Morgan Stanley lowered the price target on Mirati Therapeutics (NASDAQ: MRTX) to $60.00 from $70.00 while maintaining an Equalweight rating.BMO ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE